Concerning novel anti-cancer drugs, checkpoint inhibitors (CPIs) reactivate T lymphocytes to recognize cancer cells by blocking cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1) but may induce several immune-related adverse effects. This evidence concerns the gene CTLA4 and cancer.